...
首页> 外文期刊>Journal of Contemporary Brachytherapy >Interventional radiotherapy as exclusive treatment for primary nasal vestibule cancer: single-institution experience
【24h】

Interventional radiotherapy as exclusive treatment for primary nasal vestibule cancer: single-institution experience

机译:介入放疗作为原发性鼻前庭癌的独家治疗:单机构经验

获取原文
           

摘要

Introduction The aim of this paper was to evaluate treatment outcomes following interventional radiotherapy (brachytherapy – BT) for nasal vestibule cancer. Material and methods Considering histological diagnosis and staging, a multidisciplinary tumor board indicated an exclusive interventional radiotherapy for all patients. Plastic tubes were placed mainly with interstitial approach. The total dose was 44 Gy in 14 fractions, 3 Gy/fraction (except for the first and last fractions, 4 Gy), 2 fractions per day (b.i.d.), 5 days a week. Inclusion criteria for this analysis were: patients affected by squamous cell carcinoma with follow-up more than 6 months. Results 20 patients with primary nasal vestibule cancer were treated with IRT from May 2012 to June 2019. We excluded 4 patients due to follow-up less than 6 months and 2 patients affected by basal cell carcinoma. In total, 14 consecutive previously untreated patients were considered for definitive analysis, median age was 67.5 (range, 51-83) years, median follow-up was 53 (range, 6-84) months. All patients followed the protocol except one, who received a total dose of 42 Gy in 12 fractions, 3 Gy per 6 fractions, and 4 Gy per 6 fractions. Local control at 12, 24, and 36 months was 85.7%. Overall survival at 12 months was 92.3%, at 24 months was 76.9%, and at 36 months was 69.2%. Staging system proposed by Wang was statistically significant on local control (LC), disease-free survival (DFS), disease-specific survival (DSS), and overall survival (OS). Excellent cosmetic results were observed. Conclusions This study confirms that interventional radiotherapy could be considered as a definitive treatment in nasal vestibule cancer with excellent oncological and cosmetic outcomes.
机译:简介本文的目的是评估鼻前癌介入放疗(Brachyherapy - BT)后的治疗结果。考虑组织学诊断和分期的材料和方法,多学科肿瘤板表明了所有患者的独家介入放疗。塑料管主要以间质性的方式置于。在14个级分,3GY /级分(第一个和最后一分,4 Gy),每天2个级分,每周5天,总剂量为44μg。纳入该分析的标准是:受鳞状细胞癌影响的患者随访超过6个月。结果2012年5月至2019年6月,使用IRT治疗原发性鼻前庭癌的20名患者。我们排除了4名患者,由于后续少于6个月,2例受基础细胞癌影响的2例。总共连续14名以前未经处理的患者被认为是确定的分析,中位年龄为67.5(范围,51-83)岁,中位随访时间为53(范围,6-84)个月。所有患者均遵循除一的方案,他们在12分馏分中获得42倍的总剂量,每6个级分3Gy,每6分级分4 Gy。局部控制12,24和36个月为85.7%。 12个月的整体存活率为92.3%,24个月为76.9%,在36个月内为69.2%。王先生提出的分期系统在局部对照(LC),无病生存(DFS),疾病特异性存活(DSS)和总存活(OS)上具有统计学意义。观察到出色的化妆品结果。结论本研究证实,介入放疗可以被视为具有优异的肿瘤和化妆品结果的鼻前庭癌症的最终治疗。
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号